Role and progress of allogeneic hematopoietic stem cell transplantation in the treatment of refractory/relapsed diffuse large B-cell lymphoma
10.3760/cma.j.cn121090-20231017-00213
- VernacularTitle:异基因造血干细胞移植治疗难治/复发弥漫大B细胞淋巴瘤的作用及其进展
- Author:
Leqing CAO
1
;
Xiaodong MO
Author Information
1. 北京大学人民医院，北京大学血液病研究所，国家血液系统疾病临床医学研究中心，造血干细胞移植治疗血液病北京市重点实验室，北京 100044
- From:
Chinese Journal of Hematology
2024;45(3):308-312
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non Hodgkin's lymphoma. The current treatment plan can significantly improve the prognosis of patients, but about 30%-40% of DLBCL patients still experience drug resistance and relapse after treatment. For patients with refractory/relapse DLBCL, clinical treatment remains difficult and their prognosis is poor. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the most important curative methods for refractory/relapse DLBCL patients. This article will review the role and progress of allo-HSCT in the treatment of refractory/relapse DLBCL.
